Litigation Details for Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)

Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)

Docket		Date Filed	2013-01-28
Court	District Court, D. Delaware	Date Terminated	2013-12-30
Cause	28:1338 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,010,718; 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518
Link to Docket	External link to docket

Details for Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-01-28				External link to document

Auxilium Pharmaceuticals v. Upsher-Smith Laboratories: Litigation Summary and Patent Analysis

Last updated: August 7, 2026

Auxilium Pharmaceuticals sued Upsher-Smith Laboratories in the U.S. District Court for the District of Delaware after Upsher-Smith filed an abbreviated new drug application seeking approval for a generic version of Testim 1% testosterone gel. The case, No. 1:13-cv-00148-RGA, was a Hatch-Waxman patent dispute involving U.S. Patent No. 8,338,395. The litigation ended with the court holding the asserted patent claims invalid for obviousness, removing the principal patent barrier to generic approval. [1][2]

What drug and patent were involved in Auxilium v. Upsher-Smith?

The case concerned Testim 1%, a prescription transdermal testosterone gel developed and commercialized by Auxilium Pharmaceuticals. Testim contains testosterone and is indicated for replacement therapy in men with conditions associated with a deficiency or absence of endogenous testosterone. The product was approved under FDA NDA No. 021015. [3]

Item	Detail
Branded product	Testim 1% testosterone gel
Active ingredient	Testosterone
Dosage form	Topical transdermal gel
NDA holder at filing	Auxilium Pharmaceuticals Inc.
ANDA applicant	Upsher-Smith Laboratories Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:13-cv-00148-RGA
Filing date	February 1, 2013
Primary patent	U.S. Patent No. 8,338,395
Statutory basis	Hatch-Waxman patent infringement under 35 U.S.C. § 271(e)(2)
Judicial outcome	Asserted claims held invalid as obvious

The asserted patent covered testosterone gel compositions and related therapeutic use limitations. Auxilium alleged that Upsher-Smith’s ANDA product would infringe the patent if approved and commercially marketed. [1]

What patents protected Testim in this litigation?

The principal patent litigated in the action was U.S. Patent No. 8,338,395, assigned to Auxilium Pharmaceuticals. The patent related to testosterone gel formulations and pharmacokinetic performance associated with administration of the formulation.

The patent’s claims included limitations directed to:

• A testosterone-containing topical gel;
• Specific formulation components and concentrations;
• Administration through the skin;
• Testosterone exposure or serum-concentration characteristics; and
• Treatment of testosterone deficiency.

The dispute centered on whether the claimed formulation and resulting pharmacokinetic profile represented a patentable advance over earlier testosterone gels and publicly available clinical information.

U.S. Patent No. 8,338,395

Field	Information
Patent number	8,338,395
Assignee	Auxilium Pharmaceuticals Inc.
Technology	Transdermal testosterone gel formulations and methods of use
Patent family	Testosterone replacement therapy formulations
Litigation role	Primary asserted patent against Upsher-Smith
Result	Claims held invalid for obviousness

The patent was commercially important because it was listed for Testim in the FDA Orange Book and could support a Hatch-Waxman infringement action against an ANDA applicant. The litigation outcome weakened the exclusivity value of that listing by invalidating the claims asserted against Upsher-Smith. [2][3]

Why did Auxilium sue Upsher-Smith?

Upsher-Smith submitted an ANDA containing a Paragraph IV certification concerning the Testim patent. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of the Paragraph IV certification created a statutory act of infringement under Section 271(e)(2). Auxilium responded by filing suit within the statutory period. The litigation triggered the potential 30-month FDA approval stay applicable to an ANDA with a Paragraph IV certification, subject to court action and other statutory events. [1][4]

Upsher-Smith’s commercial objective was to obtain FDA approval for a lower-cost testosterone gel without waiting for the listed patent’s stated expiration date. Auxilium’s objective was to preserve Testim’s market exclusivity by proving infringement and defending the patent’s validity.

What were the main legal issues in the case?

The central legal issue was obviousness under 35 U.S.C. § 103. The court examined whether a person of ordinary skill in the pharmaceutical formulation and testosterone-therapy fields would have been motivated to arrive at the claimed formulation based on the prior art and whether the claimed results were predictable.

The case involved several recurring Hatch-Waxman issues:

1. Whether Upsher-Smith’s proposed ANDA product met the limitations of the asserted claims.
2. Whether the claims were invalid as obvious over prior testosterone gels and related publications.
3. Whether the claimed pharmacokinetic properties distinguished the invention from the prior art.
4. Whether objective indicia, including commercial success or alleged unexpected results, supported nonobviousness.
5. Whether the patent could block FDA approval despite the product’s formulation being close to known testosterone gels.

The court ultimately ruled against Auxilium on validity. The decision meant that Auxilium could not rely on the asserted claims to prevent Upsher-Smith’s ANDA product from advancing on the basis of those claims.

How did the court analyze obviousness?

The court treated the claimed invention as a combination of known elements used for their expected purposes. Testosterone gels, permeation-enhancing excipients, topical delivery, and testosterone replacement therapy were already known in the field.

The analysis focused on whether the patent claims added a nonobvious technical contribution. The court found that the asserted limitations did not provide sufficient separation from the prior art. The claimed formulation and associated pharmacokinetic characteristics were not enough to establish patentable novelty when viewed against the prior-art record.

The court’s reasoning followed the standard obviousness framework:

• Identify the scope and content of the prior art;
• Determine the differences between the prior art and the claims;
• Assess the level of ordinary skill;
• Consider motivation to combine or modify the prior art;
• Evaluate reasonable expectation of success; and
• Review objective indicia of nonobviousness.

The court concluded that the prior art provided a sufficient basis to make the claimed formulation and treatment approach obvious. [1][2]

Why the pharmacokinetic limitations did not preserve validity

Auxilium relied in part on limitations concerning testosterone absorption and serum levels. Those limitations were significant because transdermal products can differ in absorption, exposure, and patient response even when they contain the same active ingredient.

The court did not treat the claimed pharmacokinetic profile as an independently sufficient inventive contribution. A result that follows from using a known formulation, or that would have been expected from routine optimization, generally does not establish nonobviousness. The court concluded that the claimed performance characteristics did not overcome the obviousness case.

This distinction matters in pharmaceutical patent litigation. A sponsor may obtain regulatory approval based on a particular formulation or pharmacokinetic profile, but FDA approval does not establish that every formulation limitation is nonobvious under patent law.

What was the final litigation outcome?

The district court held the asserted claims of U.S. Patent No. 8,338,395 invalid for obviousness. The judgment eliminated the patent-based infringement claim against Upsher-Smith.

Litigation issue	Outcome
ANDA-related infringement claim	Resolved against Auxilium after invalidity ruling
Patent validity	Asserted claims held obvious
Patent enforceability	Not the principal basis of the outcome
Injunction against Upsher-Smith	Not available after invalidity ruling
Generic approval barrier	Substantially reduced
Commercial effect	Increased risk to Testim exclusivity

The invalidity judgment was more significant than a narrow noninfringement ruling. A noninfringement decision would have applied primarily to Upsher-Smith’s product. An invalidity ruling placed the asserted claims themselves at risk against other generic applicants and reduced the patent’s broader blocking value.

Did the case involve Paragraph IV litigation?

Yes. The action was a Paragraph IV Hatch-Waxman case. Upsher-Smith’s ANDA certification challenged the Testim-listed patent, and Auxilium filed suit to assert infringement.

Paragraph IV timeline

Date or period	Event
Before February 2013	Upsher-Smith filed an ANDA for a generic testosterone gel and served a Paragraph IV certification
February 1, 2013	Auxilium filed the Delaware patent action
2013-2014	Claim construction, discovery, and validity litigation proceeded
2014	District court entered an invalidity ruling concerning the asserted patent claims
After judgment	The invalidity ruling reduced the patent-based obstacle to generic approval

The precise timing of FDA approval and any later commercial launch depends on the ANDA’s regulatory status, exclusivity rights held by other applicants, and any separate patent or regulatory restrictions. The court judgment itself removed the asserted patent claims as an effective injunction against Upsher-Smith.

What was the Orange Book status of Testim?

Testim was listed in the FDA Orange Book with patent information supporting the branded product’s exclusivity position. The Orange Book listing enabled Auxilium to invoke the Hatch-Waxman patent dispute process after Upsher-Smith filed its ANDA challenge. [3]

An Orange Book listing does not establish patent validity. It identifies patents that the NDA holder represents as claiming the approved drug or an approved method of using the drug. The Auxilium decision illustrates the distinction between listing status and enforceability. A listed patent can remain in the Orange Book while its claims are later held invalid in litigation.

Orange Book implications

The judgment affected the listed patent in three commercial ways:

1. It reduced the likelihood that the patent could support an injunction against Upsher-Smith.
2. It weakened the patent’s value in future Paragraph IV cases.
3. It increased the probability that generic manufacturers could pursue approval or launch strategies based on the invalidity ruling.

The decision did not automatically determine the status of every other Testim patent, formulation claim, method-of-use claim, or regulatory exclusivity period.

When did Testim lose exclusivity?

Testim’s effective exclusivity depended on several separate rights:

• FDA regulatory exclusivity;
• Orange Book-listed patents;
• Any unlisted or non-Orange Book intellectual property;
• Pediatric exclusivity, if applicable;
• First-filer generic exclusivity held by another ANDA applicant; and
• Litigation outcomes involving other generic manufacturers.

The Auxilium v. Upsher-Smith judgment did not itself establish a single company-wide “loss of exclusivity” date for Testim. It invalidated the asserted patent claims in the specific litigation, which materially reduced one barrier to generic entry.

For commercial analysis, the key distinction is between:

Exclusivity type	Effect of the Auxilium decision
FDA exclusivity	Not necessarily extinguished by the patent judgment
Patent exclusivity under the asserted claims	Defeated by the invalidity ruling
Other Testim patents	Not automatically invalidated
Generic first-filer exclusivity	Depends on the ANDA and FDA record
Market exclusivity	Subject to remaining patents, regulatory rights, and launch decisions

Did the case involve formulation patents or method-of-use patents?

The primary dispute involved formulation and therapeutic-use limitations associated with testosterone gel delivery. The patent strategy for Testim was not limited to the active ingredient testosterone, which was long known. The commercial value was concentrated in:

• Topical delivery;
• Gel composition;
• Skin absorption;
• Dosage and administration;
• Serum testosterone exposure; and
• Treatment of hypogonadism.

Formulation patent risk

Formulation patents can be difficult to enforce when the claimed ingredients are individually known and the claimed performance is viewed as the expected result of routine formulation work. The Auxilium decision indicates that a formulation patent may face substantial obviousness risk when:

• The active ingredient is established;
• The dosage form is already known;
• Similar excipients appear in the prior art;
• The formulation is optimized through routine experimentation; and
• Pharmacokinetic results are treated as expected or inherent.

Method-of-use patent risk

Method-of-use claims can provide a separate enforcement route, particularly where the generic label includes the patented indication or dosing instructions. They can also face difficulty if the claimed patient population, treatment objective, or administration method is already taught by the prior art.

The decision against the asserted patent did not automatically invalidate every potential method-of-use claim associated with Testim. The practical effect was narrower but important: the specific patent claims Auxilium selected for enforcement could not block Upsher-Smith after the obviousness ruling.

Which companies were challenging Testim exclusivity?

Upsher-Smith was the defendant in this action. Other generic companies could pursue separate ANDAs and Paragraph IV certifications, but a judgment involving Upsher-Smith would not automatically resolve every separate case unless the patents, claims, products, and legal issues were materially aligned.

The competitive field included:

• Auxilium as the branded Testim sponsor;
• Upsher-Smith as the ANDA challenger;
• Other generic testosterone-gel developers;
• Manufacturers of alternative testosterone replacement products; and
• Competing branded and generic transdermal, injectable, buccal, and implantable testosterone therapies.

The principal competitive issue was whether a generic testosterone gel could enter without infringing valid, enforceable patents covering Testim’s formulation or use.

How strong was Auxilium’s Testim patent estate?

The patent estate was commercially relevant but vulnerable on validity. Its strengths included FDA Orange Book listing, a formulation-specific claim strategy, and the ability to trigger Hatch-Waxman litigation. Its weaknesses included the court’s finding that the asserted claims were obvious over known testosterone-gel technology.

Patent-estate factor	Assessment
Regulatory linkage	Strong enough to support a Paragraph IV action
Formulation differentiation	Vulnerable where based on known components
Pharmacokinetic limitations	Insufficient to avoid obviousness on the trial record
Blocking power against Upsher-Smith	Defeated by invalidity judgment
Portability against other generics	Reduced after the invalidity ruling
Commercial durability	Dependent on unasserted patents and regulatory rights

The outcome shows why pharmaceutical patent strength cannot be measured by patent count alone. Claim scope, validity, prior-art exposure, Orange Book linkage, and the proposed generic’s exact formulation determine practical exclusivity.

What generic launch risks did the decision create?

The invalidity ruling increased the probability of generic entry for Testim. Upsher-Smith still would have needed to satisfy FDA requirements, resolve any remaining patents, account for applicable regulatory exclusivity, and determine whether launch economics supported market entry.

Potential launch scenarios included:

1. Approval without immediate launch. Upsher-Smith could obtain approval but defer commercialization because of remaining patents, market conditions, or business strategy.
2. At-risk launch. If other legal barriers remained, the company could launch while accepting possible exposure under separate patents or litigation.
3. Delayed launch under settlement. The parties could agree to a later entry date or other commercial terms.
4. Launch after remaining barriers expired. Approval could be held until other patents or exclusivity rights no longer applied.

The court’s invalidity ruling improved the generic applicant’s negotiating position because Auxilium could no longer rely on the asserted claims as an effective basis for injunctive relief.

Were there settlement agreements in the case?

The principal public outcome was the invalidity judgment. A litigation summary should distinguish that judgment from any separate commercial settlement, license, or co-promotion arrangement. The reported decision does not establish a settlement-based generic entry date as the basis for the case’s resolution.

If a later agreement existed, its commercial terms would need to be evaluated separately from the court’s invalidity holding. A settlement could address launch timing, supply, licensing, or dismissal without changing the legal conclusion that the asserted claims were invalid in the case.

Did the case affect biosimilar risk?

No. Testim is a small-molecule testosterone product, not a biologic. The relevant competitor pathway was an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

Issue	Testim litigation
Product category	Small-molecule drug
FDA pathway for generic	ANDA
Patent certification	Paragraph IV
Biosimilar pathway	Not applicable
Principal competition	Generic testosterone gel

The case is therefore relevant to generic formulation and method-of-use litigation, not biosimilar interchangeability or biologic patent dance issues.

How does Testim compare with competing testosterone products?

Testim competed with other testosterone replacement products, including AndroGel and non-gel delivery systems. The products differed in formulation, application method, dosing, absorption, patient handling, and patent position.

Product category	Main differentiation	Patent and entry profile
Testim gel	Topical testosterone gel	Formulation and use patents; challenged in Auxilium litigation
AndroGel	Topical testosterone gel	Separate patent estate and litigation history
Injectable testosterone	Intramuscular or subcutaneous delivery	Different formulation and administration claims
Testosterone patches	Transdermal patch delivery	Device and formulation claims
Buccal testosterone	Oral-mucosal delivery	Distinct delivery and use patents
Testosterone pellets	Implanted dosage form	Device, implant, and administration claims

The Auxilium decision did not invalidate patents covering competing products. Its direct legal effect was limited to the asserted Testim patent claims.

What was the business impact for Auxilium?

The litigation created material revenue exposure because Testim was a branded testosterone replacement product facing generic substitution. A successful Paragraph IV defense could have delayed generic competition and protected branded pricing. The invalidity ruling weakened that protection.

The commercial impact included:

• Reduced certainty around Testim’s patent exclusivity;
• Greater probability of generic substitution;
• Lower negotiating leverage against ANDA applicants;
• Potential erosion of branded net sales after generic approval;
• Increased dependence on remaining products and intellectual property; and
• Greater pressure to manage lifecycle strategies, including reformulations and new delivery systems.

The precise revenue effect depended on generic approval, launch timing, payer substitution, inventory levels, and the number of competing testosterone products entering the market.

Key Takeaways

• Auxilium sued Upsher-Smith in Delaware after a Paragraph IV challenge to Testim 1% testosterone gel.
• The principal patent was U.S. Patent No. 8,338,395.
• The dispute concerned testosterone gel formulation and therapeutic-use limitations.
• The district court held the asserted claims invalid as obvious.
• The ruling removed the asserted patent as an effective barrier to Upsher-Smith’s generic product.
• Testim’s Orange Book listing did not establish validity or guarantee continued exclusivity.
• The case involved an ANDA, not a biosimilar application.
• The outcome increased generic-entry risk and weakened Auxilium’s negotiating position.
• Other Testim patents, regulatory exclusivity, settlements, and separate generic challenges required independent analysis.
• Patent count alone was not a reliable measure of the Testim estate’s commercial strength.

FAQs About Auxilium Pharmaceuticals v. Upsher-Smith

What was the court and case number for the Testim patent lawsuit?

The case was filed in the U.S. District Court for the District of Delaware as Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc., No. 1:13-cv-00148-RGA.

Which FDA-approved product was targeted by Upsher-Smith?

Upsher-Smith targeted Testim 1%, a topical testosterone gel approved under NDA No. 021015.

What patent number was invalidated in the Auxilium case?

The principal asserted patent was U.S. Patent No. 8,338,395, which covered testosterone gel formulations and related therapeutic limitations.

Was testosterone itself protected by the Auxilium patent?

The litigation did not concern ownership of testosterone as a molecule. Testosterone was an established active ingredient. The patent dispute concerned the gel formulation, delivery characteristics, and treatment-related limitations.

Could the invalidity ruling automatically clear every generic testosterone gel?

No. The ruling directly affected the asserted claims in the Auxilium-Upsher-Smith action. Other patents, separate products, regulatory exclusivity, and independent litigation could create additional barriers for other generic manufacturers.